Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE®) in the management of hemophilia A

Vascular Health and Risk Management

Volumn 3, Issue 5, 2007, Pages 555-565

  Shapiro, Amy D ^a  

^a INDIANA HEMOPHILIA AND THROMBOSIS CENTER   (United States)

Author keywords

ADVATE ; Factor VIII; Hemophilia; Octocog alpha

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR CONCENTRATE; HELIXATE FS; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; BIOEQUIVALENCE; BLEEDING DISORDER; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST CONTROL; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FEVER; HEMATOCRIT; HEMOPHILIA A; HOME CARE; HOT FLUSH; HUMAN; IMMUNOLOGICAL TOLERANCE; INJECTION SITE EDEMA; INJECTION SITE PRURITUS; LABORATORY TEST; LIVER DYSFUNCTION; LYMPHANGITIS; MANAGED CARE; MIGRAINE; NAUSEA; NONHUMAN; PERIOPERATIVE PERIOD; POSTOPERATIVE HEMORRHAGE; REVIEW; RIGOR; SIDE EFFECT; SWEATING; TASTE DISORDER; THORAX PAIN;

ALBUMINS; ANIMALS; DRUG TOXICITY; FACTOR VIII; HEMOPHILIA A; HUMANS; PLASMA; RECOMBINANT PROTEINS;

EID: 36148939080     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. AHCDC, Association of Hemophilia Clinic Directors of Canada website. [online] Accessed 11/20/2006. URL: http://www.ahcdc.ca/ vWDManagement.html.
2. Arnold DM, Julian JA, Walker IR. Association of hemophilia Clinic Director of Canada, 2006. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood, 108:460-4.
3. Arun B, Kessler CM. 2000. Clinical manifestations and therapy of the hemophilias. In: Colman, RW, Clowes, AW, Hirsh, J, et al. eds. Hemostasis and thrombosis: basic principles and clinical practice. 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins.
4. Astermark J, Donfield SM, DiMichele DM, et al. 2007. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) study. Blood, 109:546-51.
5. Batorova A, Martinowitz U. 2002. Continuous infusion of coagulation factors. Haemophilia, 8:170-77.
6. Blanchette VS, Manco-Johnson M, Santagostino E, et al. 2004. Optimizing factor prophylaxis for the haemophilia population: where do we stand? Haemophilia, 10(Suppl 4):97-104.
7. Blanchette V, Shapiro A, Liesner R, et al. 2006. ADVATE Antihemophilic Factor Plasma/Albunim Free Method (rAHF-PFM): Pharmacokinetics, safety and efficacy in previously treated patients less than 6 years old [poster]. The Hemophilia 2006 World Congress. Vancouver, Canada.
8. Bray GL, Gomperts ED, Courter S, et al. 1994. A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group. Blood, 83:2428-35.
9. Brown P. 2001. Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob disease. BMJ, 322:841-4.
10. CDC. 2005. Centers for Disease Control and Prevention. Report on the Universal Data Collection Program. 7(1):9.
11. Chan WW, Friedman H, Li-McLeod J. 2005. Impact of HIV and HCV co-infection on hospitalization and resource use among hemophilia enrollees in a managed care population. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C.
12. Collins P, Blanchette V, Fischer K, et al. 2006. Clinical implications of pharmacokinetic variables in the management of patients with severe hemophilia A [poster]. Blood, American Society of Hematology 2006. Orlando, Florida.
13. DiMichele D. 2002. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia, 8:280-7.
14. Dunn AL, Abshire TC. 2006. Current issues in prophylactic therapy for persons with hemophilia. Acta Haematol, 115:162-71.
15. EHC, European Haemophilia Consortium website. [online]. Accessed 20 Nove 2006. URL: http://www.wth.org/2/docs/Resources/EHC/ EHC_Fact-sheet_2006.pdf
16. EPAR Helixate NexGen. Scientific Discussion [online]. Accessed 16 Feb 2007. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Helixatenexgen/ 301100en6.pdf.
17. EPAR Kogenate Bayer. Scientific Discussion. [online] Accessed 16 Feb 2007. URL: htto://www.emea.europa.eu/humandocs/PDFs/EPAR/Kogenatebayer/ 101600en6.pdf.
18. Eriksson RK, Fenge C, Lindner-Olsson E, et al. 2001. The manufacturing process for B-domain deleted recombinant factor VIII. Semin Hematol, 38:24-31.
19. Ewenstein BM, Collins P, Tarantino MD, et al. 2004. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumine-free method. Semin Hematol, 41 (1, Suppl 2):1-18.
20. [FDA] Food and Drug Administration; Center for Biologics Evaluation and Research. 2006. Transmissible Spongiform encephalopathies advisory committee meeting. December 15, 2006, Issue Summary.
21. Fernandez M, Yu T, Bjornson E, et al. 2006. Stability of ADVATE, Anti-hemophilic Factor (Recombinant) Plasma/Albumin-Free Method, during simulated continuous infusion. Blood Coagul Fibrinolysis, 17:165-71.
22. Gruppo R, Collins P, Shapiro A, et al. 2006. Long-term clinical evaluation of safety, efficacy and immunogenicity of rFVIII Plasma/ Albumin-Free Method (rAHF-PFM) in previously treated hemophilia A patients - Final Report [poster], The Hemophilia 2006 World Congress. Vancouver, Canada.
23. Hilgartner MW. 2002. Current treatment of hemophilic arthropathy. Curr Opin Pediatr, 14:46-9.
24. Hoots WK. 2001. History of plasma-product safety. Transfus Med Rev, 15:3-10.
25. Horowitz B, Prince AM, Horowitz MS, et al. 1993. Viral safety of solvent-detergent treated blood products. Dev Biol Stand, 81:147-61.
26. Jiang R, Monroe T, McRogers R, et al. 2002. Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia, 8 (SuppI 2):1-5.
27. Kasper CK, Aledort LM, Counts RB, et al. 1975. A more uniform measurement of factor FVIII inhibitors. Thromb Diath Haemorrh, 34:869-72.
28. Kempton CL, Soucie JM, Abshire TC. 2006. Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates. Journ Thromb Haemost, 4:2576-81.
29. Key N. 2004. Inhibitors in congenital coagulation disorders. Br J Haematol, 127:379-91.
30. Kwon J, Stuart R. 2006. Addressing the need for improved convenience in hemophilia therapy: A vial reduction analysis in the United States. The Hemophilia 2006 World Congress. Vancouver, Canada.
31. Li-McLeod J, Friedman H, Tencer T, et al. 2006. Evaluation of office care for hemophilia patients with HIV and HCV co-infection in a managed care population. Hemophilia 2006 World Congress. Vancouver, Canada.
32. Llewelyn CA, Hewitt PE, Knight RS, et al. 2004. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet, 363:417-21.
33. Lusher JM. 2000. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials. Haematologica, 85:2-5; discussion: 5-6.
34. Luu H, Spotts G, Ewenstein B. 2006. Immunogenicity profile of ADVATE antihemophilic factor (recombinant), plasma/albumin-free method (rAHF-PFM) [poster]. The Hemophilia 2006 World Congress. Vancouver, Canada.
35. Manco-Johnson MJ. 2003. Update on treatment regimens: prophylaxis versus on-demand therapy. Semin Hematol, 44(3, Suppl 3):3-9.
36. MASAC #177, 2006. Recommendations for physicians treating patients with hemophilia A and B, von Willebrand Disease, and other congenital bleeding disorders.
37. Medical Advisory #406,2006. FDA confirms low risk for Creutzfeldt-Jakob disease among persons using plasma-derived factor VIII products licensed in the US.
38. Negrier C, Shapiro A, Berntop E, et al. 2006. Clinical efficacy and safety evaluation of ADVATE Antihemophilic Factor (Recombinant), Plasma/ Albumin-Free Method (rAHF-PFM) during surgical and invasive procedures [poster]. The Hemophilia 2006 World Congress. Vancouver, Canada.
39. NH. 2006. New government contracts for recombinant haemophilia products (July 2006). National Hemophilia, 154:1-4.
40. Package Insert. ADVATE® [Antihemophilic factor (recombinant), plasma/ albumin-free method] Prescribing Information, Baxter BioScience.
41. Package Insert. Kogenate FS® [Antihemophilic Factor (Recombinant), Formulated with Sucrose] Package Insert, Bayer HealthCare.
42. Package Insert. ReFacto® [Antihemophilic Factor (Recombinant)] Prescribing Information, Wyeth Pharmaceuticals, Inc.
43. Package Insert. Recombinate® [Antihemophilic Factor (Recombinant]) Prescribing Information, Baxter BioScience.
44. Parti R, Lee H, Yang L, et al. 2006. Stability of plasma/albumin free full-length human factor FVIII (ADVATE rAHF-PFM) after temperature cycling between refrigerated and room temperature. The Hemophilia 2006 World Congress. Vancouver, Canada.
45. Parti R, Schoppmann A, Lee H, et al. 2005. Stability of lyophilized and reconstituted plasma/albumin-free recombinant human factor VIII (ADVATE rA-HF-PFM). Haemophilia, 11:492-6.
46. Product Monograph, ADVATE [Antihemophilic Factor (Recombinant), Plasma-Albumin-Free Method] 2004, Baxter BioScience.
47. Recht M, Shapiro A. 2005. Induction of immune tolerance utilizing third generation recombinant factor VIII [ADVATE]: A report of three cases (Poster]. ISTH. Sydney, Australia.
48. Rosendaal FR, Smit C, Varekamp I, et al. 1990. Modern haemophilia treatment: medical improvements and quality of life. J Intern Med, 228:633-40.
49. Shapiro A, Abshire T, Hernandez F, et al. 2006. Efficacy and safety of ADVATE rA-HF-PFM for perioperative management of hemostasis in previously treated children with hemophilia A [poster]. The Hemophilia 2006 World Congress. Vancouver, Canada.
50. Tarantino MD, Collins PW, Hay CR, et al. 2004. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/ albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia, 10:428-37.
51. UKHCDO 2003. United Kingdom Haemophilia Centre Doctors' Organisation. Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. Haemophilia, 9:1-23.
52. Valentino LA, Oza VM. 2006. Blood safety and the choice of antihemophilic factor concentrate. Pediatr Blood Cancer, 47:245-54.
53. Valentino LA, Recht M, DiPaola J, et al. 2006. Experience with a third-generation recombinant factor VIII concentrate (ADVATE) for the induction of immune tolerance. Hemophila 2006 World Congress. Vancouver, Canada.
54. White GC 2nd, Courter S, Bray GL, et al. 1997. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost, 77:660-7.
55. White GC, DiMichele D, Mertens K, et al. 1999. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Thromb Haemost, 81:462.
56. Wight J, Paisley S, Knight C. 2003. Immune tolerance induction inpatients with haemophilia A with inhibitors: a systematic review. Haemophilia, 9:436-63.